Rhenman & Partners Asset Management AB Acquires 67,000 Shares of The Cooper Companies, Inc. $COO

Key Points

• Rhenman & Partners Asset Management AB boosted its stake in Cooper Companies by 39.4%, buying 67,000 shares to hold 237,000 shares worth about $16.25 million, making COO its 20th largest position.
• Q1 EPS beat: Cooper reported $1.10 EPS vs. $1.03 expected and raised FY26 EPS and free‑cash‑flow guidance citing strength in MyDay and MiSight, but the stock fell ~4.6% as revenue was roughly in line and investors flagged regional headwinds.
• Insiders and analysts: Insiders bought 16,014 shares (~$1.3M) in the last three months; analysts are mixed but tilted positive with a consensus "Moderate Buy" and an average target of $90.79, while some firms raised targets (Barclays $103, Needham $101).

Rhenman & Partners Asset Management AB lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 39.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 237,000 shares of the medical device company's stock after buying an additional 67,000 shares during the period. Cooper Companies comprises 1.8% of Rhenman & Partners Asset Management AB's holdings, making the stock its 20th largest position. Rhenman & Partners Asset Management AB owned approximately 0.12% of Cooper Companies worth $16,249,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. First Trust Advisors LP increased its position in shares of Cooper Companies by 30.1% in the third quarter. First Trust Advisors LP now owns 177,332 shares of the medical device company's stock valued at $12,158,000 after acquiring an additional 40,998 shares during the last quarter. Ramirez Asset Management Inc. boosted its position in Cooper Companies by 78.3% during the third quarter. Ramirez Asset Management Inc. now owns 3,943 shares of the medical device company's stock valued at $270,000 after purchasing an additional 1,731 shares during the last quarter. Gabelli Funds LLC grew its stake in Cooper Companies by 1.8% in the third quarter. Gabelli Funds LLC now owns 113,000 shares of the medical device company's stock valued at $7,747,000 after purchasing an additional 2,000 shares in the last quarter. Cramer Rosenthal Mcglynn LLC bought a new stake in shares of Cooper Companies during the 3rd quarter worth approximately $7,495,000. Finally, Crossmark Global Holdings Inc. raised its stake in shares of Cooper Companies by 10.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,107 shares of the medical device company's stock worth $624,000 after purchasing an additional 825 shares in the last quarter. Institutional investors own 24.39% of the company's stock.

Cooper Companies Stock Down 4.6%

Cooper Companies stock opened at $76.55 on Friday. The company's 50-day moving average price is $82.11 and its two-hundred day moving average price is $75.98. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. The stock has a market cap of $14.94 billion, a P/E ratio of 37.90, a P/E/G ratio of 2.19 and a beta of 1.02. The Cooper Companies, Inc. has a twelve month low of $61.78 and a twelve month high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.03 by $0.07. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.02 billion. Cooper Companies had a return on equity of 10.36% and a net margin of 9.67%.The business's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Insiders Place Their Bets

In other news, Director Cynthia L. Lucchese bought 1,784 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was bought at an average price of $84.06 per share, with a total value of $149,963.04. Following the completion of the acquisition, the director owned 9,445 shares of the company's stock, valued at $793,946.70. This represents a 23.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 17th. The stock was acquired at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the purchase, the director directly owned 7,777 shares of the company's stock, valued at $641,602.50. This represents a 34.62% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 16,014 shares of company stock worth $1,304,416 over the last three months. 2.08% of the stock is currently owned by corporate insiders.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 beat and guidance lift — COO reported a Q1 EPS beat and management raised FY26 EPS and free‑cash‑flow guidance, citing robust momentum in MyDay and MiSight and margin expansion. This is the main fundamental positive supporting longer‑term upside. Read More.
• Positive Sentiment: Bullish analyst activity — Multiple firms increased targets/ratings today (Barclays raised its target to $103 and Needham to $101; William Blair maintained a Buy), signaling continued conviction from several sell‑side analysts. This creates potential catalyst if buyers follow through. Read More.
• Neutral Sentiment: Favorable growth profile highlighted by screens — Recent writeups (Zacks, other screens) point to above‑average financial growth and attractive style scores, which may keep the stock on growth‑oriented portfolios but don’t guarantee near‑term momentum. Read More.
• Neutral Sentiment: Product/clinical news supports long run thesis — CooperVision research and product initiatives were highlighted at NCC 2026, reinforcing the durability of the contact‑lens franchise. That’s positive strategically but not an immediate catalyst. Read More.
• Negative Sentiment: Market punished the stock despite the beat — Several outlets noted shares fell after the report because revenue was roughly in‑line or slightly short of some street models and investors flagged regional headwinds and sluggish core vision trends. That helped drive the intraday selloff. Read More.
• Negative Sentiment: Mixed analyst/street positioning — Citigroup trimmed its target to $87 and issued Neutral, and Morgan Stanley stayed on Hold, reflecting differing views on near‑term recovery in core vision that can limit upside until clearer top‑line improvement is visible. Read More.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, December 5th. Barclays lifted their price objective on shares of Cooper Companies from $98.00 to $103.00 and gave the company an "overweight" rating in a research report on Friday. Robert W. Baird upped their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the company an "outperform" rating in a report on Friday, December 5th. Weiss Ratings upgraded shares of Cooper Companies from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, January 12th. Finally, Rothschild & Co Redburn cut Cooper Companies from a "buy" rating to a "neutral" rating and set a $85.00 price target for the company. in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $90.79.

Cooper Companies Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.